Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Blend · Fidelity

Invenomic Fund Invenomic Fund Institutional Class shares (BIVIX)

Ticker BIVIX · Since 2017-06-19 · · Holdings as of Jul 31, 2026

Expense ratio
3.05%$305/yr per $10k
5-yr return
+21.9%annualized
1-yr return
+4.6%as of Dec 2025
Net assets
$854.8Mall share classes
Holdings
219

Bottom line

Is BIVIX a good fund? The bottom line

BIVIX is a share class of Invenomic Fund, a managed large blend mutual fund from Fidelity.

Its expense ratio is 3.05% — about $305 a year on every $10,000 invested, more expensive than 99% of large blend funds we track.

It returned +4.6% over one year, +21.9% a year over five years (as of Dec 31, 2025, per its prospectus).

With $855 million in net assets and 219 holdings, its largest position is First American Funds Inc (8.8%) and the top 10 make up 35.2% of the portfolio.

What stands out

  • 5-year return beat 100% of category peers
  • Broadly diversified (219 holdings)
  • No front-end sales load

What to watch

  • Expensive for its category (3.05%)
  • High turnover (197% a year) can mean more taxable distributions

Updated Nov 19, 2026

What BIVIX invests in

The investment objective of the Invenomic Fund (the ?Fund?) is to seek long term capital appreciation.

T he Fund invests primarily in both long and short positions in equity securities principally traded in United States markets. Under normal market conditions, the Adviser seeks to be fully invested in the long portfolio (greater than 80%), while allowing the size of the short portfolio to fluctuate based on the market opportunity. The long positions are identified by the Fund?s adviser, Invenomic Capital Management, LP (the ?Adviser?) as securities that are both undervalued and timely, where the Adviser believes that the return potential compensates for the risk involved. The short positions are identified as securities that the Adviser believes are overvalued and that the price of the security will fall, delivering both a positive return for the Fund while simultaneously reducing the overall risk of the portfolio. The Adviser evaluates long and short positions on multiple…

From the fund's prospectus (filed Mar 2, 2026).

BIVIX performance

Fund calendar-year total returns, 2018–2025 2018: +3.7%; 2019: +11.6%; 2020: +11.5%; 2021: +61.3%; 2022: +49.9%; 2023: +16.6%; 2024: −8.8%; 2025: +4.6% +4% 2018 +12% 2019 +12% 2020 +61% 2021 +50% 2022 +17% 2023 −9% 2024 +5% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
BIVIX+4.6%+21.9%—
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full BIVIX performance history →

What BIVIX costs

On a $10,000 investment, BIVIX's 3.05% expense ratio costs about $305 a year. The prospectus estimates $3,382 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full BIVIX fee table →

BIVIX top 10 holdings

#Holding% of fund
1First American Funds Inc8.82%
2Workday Inc3.38%
3Salesforce Inc3.11%
4Universal Health Services Inc3.09%
5Global Payments Inc3.07%
6Intuit Inc2.93%
7Fidelity National Information Services Inc2.87%
8Charter Communications Inc2.81%
9Fiserv Inc2.56%
10Dentsply Sirona Inc2.54%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 35.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to BIVIX

More funds like BIVIX →

BIVIX FAQ

What is the expense ratio of BIVIX?
BIVIX's expense ratio is 3.05%, which works out to about $305 a year for every $10,000 invested. The prospectus estimates total costs of $3,382 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is BIVIX a good investment?
It depends on your goals, but the data points to: 5-year return beat 100% of category peers; broadly diversified (219 holdings); no front-end sales load; expensive for its category (3.05%); high turnover (197% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does BIVIX hold?
BIVIX's largest holdings are First American Funds Inc (8.8%), Workday Inc (3.4%), Salesforce Inc (3.1%), Universal Health Services Inc (3.1%), Global Payments Inc (3.1%). It holds 219 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is BIVIX's 5-year return?
BIVIX returned +21.9% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Does BIVIX have a sales load?
No. BIVIX has no front-end sales charge.
Who manages BIVIX?
BIVIX is offered by Fidelity through Northern Lights Fund Trust II.